Sandbox gc3: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "{| style="border: 2px solid #4479BA; align="left" ! style="width: 800px; background: #4479BA;"|{{fontcolor|#FFF|Most Common Grade ≥3 Non-Serious Adverse Events}} ! style="wi..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
{| style="border: 2px solid #4479BA; align="left" | {| style="border: 2px solid #4479BA; align="left" | ||
! style="width: 800px; background: #4479BA;"|{{fontcolor|#FFF| | ! colspan=2 style="width: 800px; background: #4479BA; text-align: left;"|{{fontcolor|#FFF|Hepatic Laboratory Abnormalities—Study GS-US-540-5773}} | ||
! style="width: 200px; background: #4479BA;"|{{fontcolor|#FFF|Remdesivir}} | ! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Remdesivir for 5 Days}} | ||
! style="width: 200px; background: #4479BA;"|{{fontcolor|#FFF| | ! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Remdesivir for 10 Days}} | ||
! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Total}} | |||
|- | |- | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | rowspan=2 style="padding: 0 5px; background: #F5F5F5; text-align: left;" | ALT Increased | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 3 | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: | | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 8/194 (4%) | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 11/191 (6%) | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 19/385 (5%) | |||
|- | |- | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 4 | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: | | style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 4/194 (2%) | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 5/191 (3%) | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 9/385 (2%) | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: | |||
| style="padding: 0 5px; background: #F5F5F5; text-align: | |||
|- | |- | ||
|} | |} |
Revision as of 21:05, 2 July 2020
Hepatic Laboratory Abnormalities—Study GS-US-540-5773 | Remdesivir for 5 Days | Remdesivir for 10 Days | Total | |
---|---|---|---|---|
ALT Increased | Grade 3 | 8/194 (4%) | 11/191 (6%) | 19/385 (5%) |
Grade 4 | 4/194 (2%) | 5/191 (3%) | 9/385 (2%) |